BRPI0507632A - compostos e composições como moduladores de lxr - Google Patents

compostos e composições como moduladores de lxr

Info

Publication number
BRPI0507632A
BRPI0507632A BRPI0507632-3A BRPI0507632A BRPI0507632A BR PI0507632 A BRPI0507632 A BR PI0507632A BR PI0507632 A BRPI0507632 A BR PI0507632A BR PI0507632 A BRPI0507632 A BR PI0507632A
Authority
BR
Brazil
Prior art keywords
compounds
compositions
lxr modulators
lxr
modulators
Prior art date
Application number
BRPI0507632-3A
Other languages
English (en)
Inventor
Valentina Molteni
Xiaolin Li
Juliet Nabakka
David Archer Ellis
Beth Anaclerio
Enrique Saez
John Wityak
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of BRPI0507632A publication Critical patent/BRPI0507632A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTOS E COMPOSIçõES COMO MODULADORES DE LXR. A presente invenção refere-se a compostos, composições farmacêuticas compreendendo tais compostos e métodos de uso de tais compostos para tratar ou prevenir doenças ou distúrbios associados com a atividade dos receptores X do fígado (LXRs).
BRPI0507632-3A 2004-02-11 2005-02-11 compostos e composições como moduladores de lxr BRPI0507632A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54384804P 2004-02-11 2004-02-11
US62302104P 2004-10-27 2004-10-27
PCT/US2005/004655 WO2005077124A2 (en) 2004-02-11 2005-02-11 Compounds and compositions as lxr modulators

Publications (1)

Publication Number Publication Date
BRPI0507632A true BRPI0507632A (pt) 2007-07-03

Family

ID=34864533

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507632-3A BRPI0507632A (pt) 2004-02-11 2005-02-11 compostos e composições como moduladores de lxr

Country Status (8)

Country Link
US (3) US8158662B2 (pt)
EP (1) EP1713799A4 (pt)
JP (1) JP5022040B2 (pt)
CN (1) CN1918155B (pt)
AU (2) AU2005211809B2 (pt)
BR (1) BRPI0507632A (pt)
CA (1) CA2553443C (pt)
WO (1) WO2005077124A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923573B2 (en) * 2004-10-27 2011-04-12 Daiichi Sankyo Company, Limited Benzene compound having 2 or more substituents
JP4854264B2 (ja) * 2004-10-27 2012-01-18 第一三共株式会社 ２以上の置換基を有するベンゼン化合物
MY153958A (en) * 2009-05-28 2015-04-30 Exelixis Patent Co Llc Lxr modulators
CA2811145A1 (en) 2010-09-07 2012-03-15 Snu R&Db Foundation Sesterterpene compound and use thereof
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ，インコーポレーテッド 金属塩及びその使用
EP4574819A1 (en) 2023-12-22 2025-06-25 Basf Se Diazinone compounds for the control of invertebrate pests
IL330217A (en) 2023-12-22 2026-08-01 Basf Se Diazinon compounds for controlling invertebrate pests

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01160976A (ja) 1987-12-18 1989-06-23 Tsumura & Co １，３，４−チアジアゾール誘導体及びそれを有効成分として含有する抗潰瘍剤
JPH01233282A (ja) 1988-03-12 1989-09-19 Tsumura & Co １，３，４−チアジアゾール誘導体及びそれを有効成分として含有する抗潰瘍剤
JPH0296577A (ja) * 1988-09-30 1990-04-09 Tsumura & Co 新規な１，３，４‐チアジアゾール誘導体および該誘導体を有効成分とする抗潰瘍剤
AU7961300A (en) 1999-10-29 2001-05-14 Yamanouchi Pharmaceutical Co., Ltd. Kainic acid neurocytotoxicity inhibitors
US6555563B1 (en) * 2001-11-16 2003-04-29 Medinox, Inc. Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
US20050036992A1 (en) 2002-12-23 2005-02-17 Irm Llc Novel use of liver X receptor agonists

Also Published As

Publication number Publication date
JP2007522242A (ja) 2007-08-09
US20090325981A1 (en) 2009-12-31
AU2009201867A1 (en) 2009-06-04
AU2005211809B2 (en) 2009-02-12
CN1918155A (zh) 2007-02-21
WO2005077124A2 (en) 2005-08-25
US20120214812A1 (en) 2012-08-23
JP5022040B2 (ja) 2012-09-12
AU2009201867A8 (en) 2013-05-30
AU2005211809A1 (en) 2005-08-25
CN1918155B (zh) 2010-05-26
CA2553443A1 (en) 2005-08-25
AU2009201867B2 (en) 2011-12-15
WO2005077124A3 (en) 2005-11-10
CA2553443C (en) 2012-03-27
AU2009201867C1 (en) 2013-05-30
US8569345B2 (en) 2013-10-29
US8158662B2 (en) 2012-04-17
AU2009201867B8 (en) 2013-05-30
EP1713799A4 (en) 2010-07-07
EP1713799A2 (en) 2006-10-25
US20130345220A1 (en) 2013-12-26

Similar Documents

Publication Publication Date Title
BRPI0512674A (pt) compostos e composições como moduladores de receptores nucleares de hormÈnio esteróide
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
WO2007092065A3 (en) Compounds and compositions as lxr modulators
AU2007257423A8 (en) Purine analogs
BRPI0507626A (pt) compostos e composiçoes como moduladores de lxr
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
BRPI0511477A (pt) compostos e composições como moduladores de ppar
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
BRPI0508085A (pt) compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0513916A (pt) moduladores de pirrol-piridina cinase
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos
BRPI0413582B8 (pt) compostos, composições e métodos para inibir a atividade de proteasome
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
BR112013008140A2 (pt) "compostos imidazotriazinona".
BRPI1013259B8 (pt) moduladores lxr
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
CO6190616A2 (es) Carboxamidas n-fenil-bipirrolidina sustituidas y su uso terapeutico
MA31889B1 (fr) N-phenyl -bipyrrolidine-urees substituees et utilisation therapeutique de celles-ci

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 11A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.